Filtered By:
Drug: Methotrexate

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 7800 results found since Jan 2013.

Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome.
Conclusion. Age continues to be a prognostic factor in osteosarcoma. Our study suggests that presentation factors are not associated with prognosis, while poorer response to chemotherapy and lower cumulative dose of chemotherapy delivered to YA patients may contribute to poorer outcomes. PMID: 24976784 [PubMed]
Source: Sarcoma - November 16, 2014 Category: Cancer & Oncology Tags: Sarcoma Source Type: research

Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.
CONCLUSIONS: The PULSE cohort had highly active multiorgan disease at diagnosis and significant disease damage at enrolment in the South African registry. South African patients have severe lupus nephritis and poor renal outcomes compared to North American peers. Our study revealed a severe disease phenotype in the PULSE cohort resulting in poor outcomes in this high-risk population. PMID: 27488473 [PubMed - as supplied by publisher]
Source: Lupus - August 2, 2016 Category: Rheumatology Authors: Lewandowski LB, Schanberg LE, Thielman N, Phuti A, Kalla AA, Okpechi I, Nourse P, Gajjar P, Faller G, Ambaram P, Reuter H, Spittal G, Scott C Tags: Lupus Source Type: research

Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients
ConclusionsUse of nitrous oxide in pediatric leukemia patients at the same time as methotrexate use should be avoided especially as many suitable alternative anesthetic agents exist. Clinicians should consider monitoring levels of vitamin B12 in patients suspected of having methotrexate-induced neurotoxic effects.
Source: Cancer Chemotherapy and Pharmacology - September 21, 2016 Category: Cancer & Oncology Source Type: research

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Conclusions: PEG can be incorporated into pediatric-inspired chemotherapy regimens w/ manageable toxicity for appropriately selected adults up to age 60 w/ Ph- ALL/LBL. While PEG-related AEs are common, few pts require permanent discontinuation of asparaginase. Grade 3-4 hyperbilirubinemia was common, particularly post-I-1, but recurred infrequently when PEG was continued. Two induction courses resulted in a high rate of MRD negativity post-I-2 and translated to a low rate of relapse. Though further follow-up is required, 3-year EFS is encouraging. Data regarding asparaginase enzyme activity and silent inactivation w/ neut...
Source: Blood - November 21, 2018 Category: Hematology Authors: Geyer, M. B., Ritchie, E. K., Rao, A. V., Cazacu, M. I., Vemuri, S., Tallman, M. S., Douer, D., Park, J. H. Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III Source Type: research

AYA ALL: Real World Experience from a Tertiary Care Center in North India
Conclusion: We have demonstrated in this study the improved outcomes of AYA-ALL who usually present in late chronic phase in resource constraint settings. Contrary to the belief, adult GMALL protocol had better survival vis-à-vis pediatric BFM protocol in this cohort of AYA-ALL.Figure.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Das, S., Yanamandra, U., Moslem, M., Kapoor, R., Pramanik, S., Kumar, R., Khurana, H., Sharma, S., Verma, T., Jasjit, S., Sharma, A., Nair, V. Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research

Development of crohn & #39;s disease following treatment for juvenile idiopathic arthritis in a nigerian child: Case report and review of literature
We report the case of a Nigerian child with JIA who developed CD following treatment for JIA. A 9-year-old male with JIA was referred to the pediatric gastroenterology unit of the Lagos University Teaching Hospital on the account of chronic diarrhea with occasional passage of bloody stools. He had been on prednisolone and methotrexate which had controlled the joint flares. Colonoscopy revealed extensive colitis, ulcers, abscesses, and ileocecal disease. Histology confirmed the CD. In view of the unavailability of the recommended treatment, namely biologics in the country and financial constraints; steroids; and sulfasalazi...
Source: Annals of African Medicine - December 4, 2019 Category: African Health Authors: Oluwafunmilayo Funke Adeniyi Uyi Ima-Edomwonyi A Emuobor Odeghe I Vincent Onyekwelu Source Type: research

Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
CONCLUSION: This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with ustekinumab. Controlled trials are warranted to fully assess the safety and efficacy of ustekinumab for treating TNF inhibitor-induced psoriasis in the pediatric population.J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.2106. PMID: 32550694 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - June 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase.
Abstract Methotrexate (MTX), an anti-folate, is administered at high-doses to treat malignancies in children and adults. However, there is considerable interpatient variability in clearance of high-dose (HD) MTX. Patients with delayed clearance are at an increased risk for severe nephrotoxicity and life-threatening systemic MTX exposure. Glucarpidase is a rescue agent for severe MTX toxicity that reduces plasma MTX levels via hydrolysis of MTX into inactive metabolites, but is only indicated when MTX concentrations are > 2 standard deviations above the mean excretion curve specific for the given dose together w...
Source: Clinical Pharmacology and Therapeutics - June 18, 2020 Category: Drugs & Pharmacology Authors: Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB Tags: Clin Pharmacol Ther Source Type: research

Pediatric Acute Toxic Leukoencephalopathy: Prediction of the Clinical Outcome by FLAIR and DWI for Various Etiologies PEDIATRICS
CONCLUSIONS: The DWI and FLAIR severity scores appear highly prognostic, whereas percentage ADC reduction is moderately prognostic for clinical outcomes in pediatric acute toxic leukoencephalopathy. Immunosuppressive pediatric acute toxic leukoencephalopathy tends toward favorable outcomes, and fludarabine tends toward worse outcomes.
Source: American Journal of Neuroradiology - August 11, 2020 Category: Radiology Authors: Ozturk, K., Rykken, J., McKinney, A. M. Tags: PEDIATRICS Source Type: research

IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival
Conclusions: OS and EFS with both regimens were similar. However, the MAP regimen was associated with a statistically significant increase in incidence of supportive care admissions, delay in next cycle of chemotherapy, and predicted higher cost of treatment.
Source: Journal of Pediatric Hematology Oncology - April 23, 2021 Category: Hematology Tags: Online Articles: Original Articles Source Type: research

A Case of Statin-Associated Autoimmune Myopathy: Management and Treatment
We present a case of a male patient who developed progressively worsening muscle weakness and elevated muscle enzyme markers upon initiation of a statin. His symptoms persisted despite a trial of an alternative statin and subsequent discontinuation of all statin medications. A multitude of possible etiologies were considered and ranged from infectious, autoimmune, cancerous, to congenital in nature. Environmental factors, such as exposure to medications or toxins, were also considered as one of the possible precipitating factors. The association between his statin consumption and muscle weakness were not easily apparent at...
Source: Primary Care - January 23, 2023 Category: Primary Care Authors: Mercedes Malone Abdelilah Lahmar Atif Siddique Michael Rozboril Jesse L Kresak Source Type: research

Four-year follow-up of surface contamination by antineoplastic drugs in a compounding unit
Conclusions From the beginning of the study and from month to month, surface contamination was limited to the nearest sampling points to the compounding unit. This 4-year monitoring study allowed us to determine the intravenous conventional antineoplastic drugs and sampling points to be focused on.
Source: Occupational and Environmental Medicine - February 14, 2023 Category: Occupational Health Authors: Saint-Lorant, G., Vasseur, M., Allorge, D., Beauval, N., Simon, N., Odou, P. Tags: Workplace Source Type: research

What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines
AbstractSystematic r eview to evaluate the quality of the clinical practice guidelines (CPG) for rheumatoid arthritis (RA) management and to provide a synthesis of high-quality CPG recommendations, highlighting areas of consistency, and inconsistency. Electronic searches of five databases and four online guideline repositories were performed. RA management CPGs were eligible for inclusion if they were written in English and published between January 2015 and February 2022; focused on adults  ≥ 18 years of age; met the criteria of a CPG as defined by the Institute of Medicine; and were rated as high quality on the ...
Source: Clinical Rheumatology - June 9, 2023 Category: Rheumatology Source Type: research

A36: Long‐term Pharmacokinetics of Body Surface Area‐Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis
Conclusion:Treatment with 30 mg/m2 SC golimumab q4w + MTX resulted in sustained steady‐state trough serum golimumab concentrations over time. The PK/efficacy correlation analyses demonstrated that the BSA‐adjusted dosing regimen of 30 mg/m2 SC golimumab q4w provided adequate drug exposure for the desired efficacy.
Source: Arthritis and Rheumatism - March 27, 2014 Category: Rheumatology Authors: Jocelyn H. Leu, Alan Mendelsohn, Joyce Ford, Hugh M. Davis, Honghui Zhou, Z. Xu Tags: Poster Presentations Source Type: research